Meta-Chlorophenylpiperasine (m-CPP), a serotonin agonist and metabolite of the
Introduction
A number of recent studies have documented the existence of significant biochemical and neuroanatomic abnormalities in the serotonin (5-HT) system in Alzheimer's disease (AD) (Yamamoto and Hirano 1985; Bowen et al 1983; Cross et al 1984 Cross et al , 1986 . The clinical correlates of 5-HT system dysfunction in AD is unknown, but altered 5-HT function may be implicated in the expression of behavioral and cognitive symptoms in this population.
We have been using the 5-HT receptor agonist, meta-chlorophenylpiperazine (m-CPP), a metabolite of the heterocyclic antidepressant Irazodone, to examine the functional correlates of 5-HT abnormalities in AD. Although the pharmacological effects of m-CPP are varied and complex, m-CPP appears_ to act pri'mari_ly as a 5-__I-IT_ ._fete_ ~r agonist, with somewhat greater potency at the 5-HT,c than at the 5-HTn^ and 5-HTas sites (Schoeffter and Hoyer 1989) . Because of the failure to demonstrate the existence of the 5-HTns receptor in human brain (Heuring et al 1986; Hoyer et al 1986) , m-CPP's effects in humans cannot be attributed to agonist activity at the 5-HTm receptor site.
In earlier studies, we established the safety of single-dose administration of m-CPP in an elderly neuropsychiatric population (Lawlor et al 1989a) and also found that AD patients showed increased behavioral responsivity to acute intravenous (IV) administration of this 5-HT agonist (Lawlor et al 1989b) . Increased behavioral responsivity was not paralleled by any differences in neuroendocrine responsivity, suggesting that subpopu-iations of 5-HT receptors remained functionally unaffected by the disease process. We postulated that the 5-HT receptors mediating certain aspects of behavior may be hyperresponsive in AD, and that a possible therapeutic sffategy could be to ~gulate s~h a hyperresponsive receptor system by chronic lreatment with an agonist or with a 5-HT reuptake inhibitor. Furthermore, thecapeutic benefit was observed during chronic m-CPP administration in a small number of depressed patients (Mellow et al 1990) .
In this study, m-CPP was administered on a chronic ~is to AD patients in a pilot double-blind, crossover study to determine whether it might be bbehavi~y active whether direct agonist administration might produce behavioral or other ~wovement in this population.
Methods
Eight patient~ meeting strict NINCDS-ADRDA criteria for "probable Al~imer's disease" (McKhann et al 1984) were entered into the study. All subjects were inpatients during the course of the study and were medically healthy as determi~ by physical examination and normal blood chemistries prior to beginning the study. ~ mean age of the patients was 68.0 _ 2.5 years, with a mean duration of fl~ss of 5.8 _ 0.8 years. All were moderately to severely affected, with ratings on the Global Deterioration Scale (GDS) (Reisberg et al 1982) and Clinical Dementia Rating Scale (CDR) (Hughes et al 1982) of 5.9 _+ 0.1 and 2.4 _+ 0.2, respectively. Al~gh none of the p~tien~ ~t criteria for Major Depression on entry to the study, patients did have measurable levels of mild depression, as evidenced by basel ~iou-re~ from the 17-item Dementia Mood Assessment Scale (D~S) (S~rland et al 1988, 1989) of 32.2 + 3.3.
Subjects received m-CPP or placebo in a double-bfind, placebo-conm3Hed, crossover fashion, randomized for order. Initial doses of m-CPP were 20 m~day, and m-CPP was increased in 20-rag increments over the fc!lowing 3-5 days to a ~mum of 80 mR/day. Capsules were administered four times a ~My, at 9:00 AM, 1:00 PM, 6:00 PM, and 10:00 PM. The duration of the placebo and active drug adminis~tion in ~s prefiminary study varied from patient to patient; the goal was to administer m-CPP for at least 2 weeks to each subject. At the completion of the drug treatment p~, ~ dose of m-CPP was nmv~ anu then d~sconunu¢~ completely ~e following day. There was no was~u-t between active drug and placebo treatment phases.
Behavioral measures included weekly ratings camed out by ~ned raters blind to the treatment condition using the Brief Psychiatric Rating Scale 03PRS) (Ove~ and Gotham 1962), modified Global Rating Scales (Bunney and Hamburg 1963) , the DMAS, and nightly sleep checks documenting the number of hours of uninterrupted sleep. Patients also had blood drawn twice a week for routine hematology and biochemis~es (including liver function tests), m-CPP blood levels (drawn at 7:30 AM prior to the morning dose) were measured in five of the eight subjects at the end of the chro~c treatment phase.
Data Analysis
The group behavioral data were analyzed using paired t-tests co~g ~ BPRS, Global Ratings, and DMAS ratings at the end of drug and ~laccL'o trea~n~. The sleep data were analyzed by repeated measures analysis of variance (ANOVA). All data are expressed as mean _ SEM, unless otherwise stated. Results m-CPP was tolerated by all subjects and no side effects related to drug treatment were reported or observed by the staff. There were no changes in blood indices during the course of the m-CPP trial that could be attributed to drug treatment. One female subject with x-ray evidence of osteoporogis at baseline (~ent 7, Table 11 ~ elevations of alkaline phosphatase (with normal SGOT and SGPT) while on m-CPP, but this was attributed to microfractures of the pelvis, as diagnosed by bone scan.
The duration of active treatment for each individual patient is shown in Table 1 . The mean daily dose of m-CPP was 55.3.4-4.2 nag and the mean durations of m-CPP treatment and placebo were 16.13 _.+ 1.72 and 12.25 __. 1.46 days, respectively. The mean plasma m-CPP concentration (only available for five subjects) measured at the completion of the chronic treatment phase was 84.0 _.+ 42.0 ng/ml.
Behavioral Ratings
Individual scores on all behavioral scales for the eight patients following m-CPP and placebo are shown in Table 1 . Five of eight patients showed increases in the DMAS and BPRS scores (indicating worsening in cfinical status) following m-CPP compared with placebo. There were no consistent changes along the individual "Global" items, in particular across meas-mes of "cognitive" or "functional impairment.'" There was no difference between mean DMAS depression-related items at baseline (prior to drug cr placebo treatments) and DMAS following placebo (32.2 __. 3.3 versus 32.6 _ 3.8), indicating that placebo treatment was not associated with any change in DMAS ratings. Following m-CPP, there were small but significant increases noted on the 17-item DMAS (32.6 +_. 3.8 versus 40.9 _.+ 4.4; p < 0.05), and on the "'vegetative" factor of the DMAS (indicating decreased sleep, appetite, and energy) (1.0 -*-0.3 versus 1.9 _ 0.5; p < 0.001). Although t.hele was no overall significant change on ~ t~ 24-item BPRS, there was a small but significant increase in the "aner~at" f~ (indic~g increased emotional withdrawal, motor retardation, blunted affect, and disot'ientation) (3.1 _+ 0.5 versus 3.5 -0.4; p < 0.001) following m-CPP compared with placebo.
Sleep Records
When mean nightly sleep records were compared, there was no overall difference between drug and placebo treatment conditions. However, consistent with ~ behavioral observation in a number of patients, comparison of the immediate m-CPP withdrawal with the chronic m-CPP treatment phase revealed significantly decreased sleep during our nights following d:ug withdrawal compared with the chronic treatment ~.
Discussion
hi this preliminary study, chronic m-CPP, in doses of up to 80 mg/day, was well tolerated and produced no significant changes in hematological or bioche~cal ~ces in a group of moderate to severely affected AD subject, m-CPP tream,.ent did result m significant, albeit small, increases in depression-related items and anergy, but produced no significant change in cognitive function in this small group of severely impairaxi patients. Interestingly, in the only other reported clinical trial with chronic dosing of ~is agent, we found improvement in depressed mood in a subgroup of depressed patients following chronic m-CPP treatment (Mellow et ai 1990) . One could postulate that ~ contrasting behavioral effects following m-CPP in these two populations could be expl~ by the serotonergic (and other) neuronal losses in AD. However, it should be noted that the behavioral changes observed in this study were modest, and were found with a s~ number of subjects. More definitive conclusions must await replication with larger patient numbers.
In conclusion, chronic 5-I-11" agonist treatment with m-CPP produced small but significant increases in depression and anergy ratings in this group of moderate to severely affected AD patients. No beneficial or deleterious effects on cognition were observed m this small group of patients. The overall negative behavioral results in Ks prelimi~ study conWast with the repor',~ -a ~itive behavioral effects of 5-HT reu~ ~bifion in dementia populations (Nyth et al 1988) , and of the effe r.s of the parent compound, trazodone, in agitated demented patients (Pinner and Rich 1988; Simpson and Foster 1986) . Future studies are warranted to explore whether 5-HT-selective agents (agonists or antagonists) are helpful in the management of noncognitive ~ cognitive symptoms inAD.
